PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26733785-8 2015 These findings suggest that (i) NT is acting on ventral midbrain NTS1 receptors to induce a rewarding effect and (ii) that this psychostimulant-like effect could be due to a direct action of NT on dopamine neurons and/or an enhancement of glutamatergic inputs to non-dopamine ([Formula: see text]) neurons. Dopamine 197-205 neurotensin Rattus norvegicus 32-34 26733785-8 2015 These findings suggest that (i) NT is acting on ventral midbrain NTS1 receptors to induce a rewarding effect and (ii) that this psychostimulant-like effect could be due to a direct action of NT on dopamine neurons and/or an enhancement of glutamatergic inputs to non-dopamine ([Formula: see text]) neurons. Dopamine 267-275 neurotensin Rattus norvegicus 32-34 25379267-3 2014 Neurotensin (NT) is a 13-amino acid neuropeptide that modulates dopamine, acetylcholine, glutamate, and GABA neurotransmission in brain reward pathways. Dopamine 64-72 neurotensin Rattus norvegicus 0-11 26198255-0 2015 Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson"s disease. Dopamine 90-98 neurotensin Rattus norvegicus 0-11 24847420-6 2014 Twenty four hours after the last injection of drug or vehicle, neurotensin contents were determined in the mesocorticolimbic and nigrostriatal dopamine regions by radioimmunoassay. Dopamine 143-151 neurotensin Rattus norvegicus 63-74 19948149-3 2010 NT69L, an analog of neurotensin(8-13), acts like an atypical antipsychotic drug in several dopamine-based animal models used to study schizophrenia. Dopamine 91-99 neurotensin Rattus norvegicus 20-31 23113260-1 2012 We studied the effects of neurotensin dipeptide analog Dilept (N-caproyl-L-prolyl-L-tyrosine methyl ester) on dopamine metabolism and synthesis in the nucleus accumbens of Wistar rats. Dopamine 110-118 neurotensin Rattus norvegicus 26-37 23685547-3 2013 Neurotensin is a peptide associated with inhibitory feedback pathways to nigrostriatal DA projections. Dopamine 87-89 neurotensin Rattus norvegicus 0-11 18835308-0 2008 Stimulation by neurotensin of dopamine and 5-hydroxytryptamine (5-HT) release from rat prefrontal cortex: possible role of NTR1 receptors in neuropsychiatric disorders. Dopamine 30-38 neurotensin Rattus norvegicus 15-26 19442653-1 2009 Neurotensin (NT) is a neuropeptide involved in cocaine reward, and in learning and memory processes related to drug use within the mesolimbic dopamine (DA) system. Dopamine 142-150 neurotensin Rattus norvegicus 0-11 19442653-1 2009 Neurotensin (NT) is a neuropeptide involved in cocaine reward, and in learning and memory processes related to drug use within the mesolimbic dopamine (DA) system. Dopamine 142-150 neurotensin Rattus norvegicus 13-15 19442653-1 2009 Neurotensin (NT) is a neuropeptide involved in cocaine reward, and in learning and memory processes related to drug use within the mesolimbic dopamine (DA) system. Dopamine 152-154 neurotensin Rattus norvegicus 0-11 19442653-1 2009 Neurotensin (NT) is a neuropeptide involved in cocaine reward, and in learning and memory processes related to drug use within the mesolimbic dopamine (DA) system. Dopamine 152-154 neurotensin Rattus norvegicus 13-15 18835308-1 2008 The modulation of cortical dopaminergic and serotonergic neurotransmissions by neurotensin (NT) was studied by measuring the release of dopamine (DA) and 5-hydroxytryptamine (5-HT) from the prefrontal cortex (PFC) of freely moving rats. Dopamine 27-35 neurotensin Rattus norvegicus 79-90 18835308-1 2008 The modulation of cortical dopaminergic and serotonergic neurotransmissions by neurotensin (NT) was studied by measuring the release of dopamine (DA) and 5-hydroxytryptamine (5-HT) from the prefrontal cortex (PFC) of freely moving rats. Dopamine 146-148 neurotensin Rattus norvegicus 79-90 18835308-4 2008 Local administration of neurotensin (1microM or 0.1microM) in the PFC via the dialysis probe produced significant, long-lasting, and concentration-dependent increase in the extracellular release of DA and 5-HT. Dopamine 198-200 neurotensin Rattus norvegicus 24-35 18991855-1 2008 Neurotensin (NT) is a tridecapeptide associated with extrapyramidal and limbic pathways and is thought to inhibit dopamine (DA) functions in nigrostriatal, mesocortical, and mesolimbic systems. Dopamine 114-122 neurotensin Rattus norvegicus 0-11 18991855-1 2008 Neurotensin (NT) is a tridecapeptide associated with extrapyramidal and limbic pathways and is thought to inhibit dopamine (DA) functions in nigrostriatal, mesocortical, and mesolimbic systems. Dopamine 114-122 neurotensin Rattus norvegicus 13-15 18991855-1 2008 Neurotensin (NT) is a tridecapeptide associated with extrapyramidal and limbic pathways and is thought to inhibit dopamine (DA) functions in nigrostriatal, mesocortical, and mesolimbic systems. Dopamine 124-126 neurotensin Rattus norvegicus 0-11 18991855-1 2008 Neurotensin (NT) is a tridecapeptide associated with extrapyramidal and limbic pathways and is thought to inhibit dopamine (DA) functions in nigrostriatal, mesocortical, and mesolimbic systems. Dopamine 124-126 neurotensin Rattus norvegicus 13-15 17988654-0 2007 The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: potentiation of risperidone-, but not haloperidol-, induced dopamine efflux. Dopamine 65-73 neurotensin Rattus norvegicus 4-15 17988654-0 2007 The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: potentiation of risperidone-, but not haloperidol-, induced dopamine efflux. Dopamine 160-168 neurotensin Rattus norvegicus 4-15 17689525-2 2007 Neurotensin is a neuropeptide associated with the regulation of the nigrostriatal and mesolimbic dopamine pathways. Dopamine 97-105 neurotensin Rattus norvegicus 0-11 17689525-4 2007 Because neurotensin has been linked with both mesolimbic and mesocortical dopamine function, we examined the impact of nicotine treatment on central nervous neurotensin systems by measuring changes in neurotensin tissue content because it has been shown that such changes reflect alterations in release and activity of this peptide system. Dopamine 74-82 neurotensin Rattus norvegicus 8-19 17689525-9 2007 These findings with previous studies, suggest that nicotine-mediated dopamine release activates D(2) receptors which in turn increases neurotensin release, turnover and acutely reduces tissue levels in the ventral tegmental area and other limbic and basal ganglia structures. Dopamine 69-77 neurotensin Rattus norvegicus 135-146 16983483-2 2007 Using mono and dualprobe(s) microdialysis in the basal ganglia of the freely moving rat evidence has been obtained that neurotensin (NT) in threshold concentrations can counteract the D(2) agonist (intrastriatally perfused) induced inhibition of striatal dopamine (DA) release and of pallidal GABA release from the striato-pallidal GABA pathway, effects that are blocked by a NTR(1) antagonist SR48692. Dopamine 255-263 neurotensin Rattus norvegicus 120-131 16983483-2 2007 Using mono and dualprobe(s) microdialysis in the basal ganglia of the freely moving rat evidence has been obtained that neurotensin (NT) in threshold concentrations can counteract the D(2) agonist (intrastriatally perfused) induced inhibition of striatal dopamine (DA) release and of pallidal GABA release from the striato-pallidal GABA pathway, effects that are blocked by a NTR(1) antagonist SR48692. Dopamine 265-267 neurotensin Rattus norvegicus 120-131 17015039-1 2006 Recently we showed that the neurotensin polyplex is a nanoparticle carrier system that targets reporter genes in nigral dopamine neurons in vivo. Dopamine 120-128 neurotensin Rattus norvegicus 28-39 16838364-1 2006 The tridecapeptide neurotensin (NT) is involved in the modulation of dopamine (DA)-mediated functions in the nigrostriatal and mesocorticolimbic pathways. Dopamine 69-77 neurotensin Rattus norvegicus 19-30 16838364-1 2006 The tridecapeptide neurotensin (NT) is involved in the modulation of dopamine (DA)-mediated functions in the nigrostriatal and mesocorticolimbic pathways. Dopamine 69-77 neurotensin Rattus norvegicus 32-34 16838364-1 2006 The tridecapeptide neurotensin (NT) is involved in the modulation of dopamine (DA)-mediated functions in the nigrostriatal and mesocorticolimbic pathways. Dopamine 79-81 neurotensin Rattus norvegicus 19-30 16838364-1 2006 The tridecapeptide neurotensin (NT) is involved in the modulation of dopamine (DA)-mediated functions in the nigrostriatal and mesocorticolimbic pathways. Dopamine 79-81 neurotensin Rattus norvegicus 32-34 16838364-12 2006 In addition, NT might have a role in affecting the interplay among the endogenous release of GABA/glutamate and DA. Dopamine 112-114 neurotensin Rattus norvegicus 13-15 12444598-4 2002 Neurotensin (10 and 100 nM), added before glutamate (30 microM) exposure, significantly enhanced the glutamate-induced reduction of [(3)H]dopamine uptake. Dopamine 138-146 neurotensin Rattus norvegicus 0-11 16882016-1 2006 Neurotensin exerts complex effects on the mesolimbic dopamine system that alter motivation and contribute to neuroadaptations associated with psychostimulant drug administration. Dopamine 53-61 neurotensin Rattus norvegicus 0-11 16882016-2 2006 Activation of abundant neurotensin receptors in the ventral tegmental area (VTA) enhances dopamine neuron activity and associated release of dopamine in the nucleus accumbens (Acb) and cortex. Dopamine 90-98 neurotensin Rattus norvegicus 23-34 16882016-2 2006 Activation of abundant neurotensin receptors in the ventral tegmental area (VTA) enhances dopamine neuron activity and associated release of dopamine in the nucleus accumbens (Acb) and cortex. Dopamine 141-149 neurotensin Rattus norvegicus 23-34 16866211-3 2006 Furthermore, the extracellular DA concentration in the NACC of 6-OHDA-treated rats was significantly increased compared to the controls following neurotensin (NT) microinjection into the ventral tegmental area (VTA). Dopamine 31-33 neurotensin Rattus norvegicus 146-157 16405028-0 2005 [The new tripeptoid neurotensin analog dilept selectively affects dopamine turnover in nucleus accumbens and hypothalamus]. Dopamine 66-74 neurotensin Rattus norvegicus 20-31 16316028-5 2005 It is supposed that neurotensin normalizing influences on behavior is connected to a restoration of balance of dopamine-and serotoninergic brain structures interaction. Dopamine 111-119 neurotensin Rattus norvegicus 20-31 15716398-4 2005 In the rat prefrontal cortex (PFC), neurotensin is exclusively localized to dopamine axons and has been suggested to be decreased in schizophrenia. Dopamine 76-84 neurotensin Rattus norvegicus 36-47 15716398-10 2005 Because neurotensin is exclusively localized to dopamine axons in the PFC, we also determined whether neurotensin plays a role in the ability of dopamine agonists to increase extracellular GABA levels. Dopamine 145-153 neurotensin Rattus norvegicus 102-113 15716398-11 2005 We found that D2 agonist-elicited increases in PFC GABA levels were blocked by pretreatment with SR48692, consistent with data indicating that D2 autoreceptor agonists increase neurotensin release from dopamine-neurotensin axons in the PFC. Dopamine 202-210 neurotensin Rattus norvegicus 177-188 15716398-11 2005 We found that D2 agonist-elicited increases in PFC GABA levels were blocked by pretreatment with SR48692, consistent with data indicating that D2 autoreceptor agonists increase neurotensin release from dopamine-neurotensin axons in the PFC. Dopamine 202-210 neurotensin Rattus norvegicus 211-222 15150532-2 2004 Many of these dopamine (DA) axons in the rat coexpress the peptide neurotransmitter neurotensin. Dopamine 14-22 neurotensin Rattus norvegicus 84-95 15150532-2 2004 Many of these dopamine (DA) axons in the rat coexpress the peptide neurotransmitter neurotensin. Dopamine 24-26 neurotensin Rattus norvegicus 84-95 12444598-9 2002 These findings support the view of a possible pathophysiological role of neurotensin in mesencephalic dopamine neuronal function. Dopamine 102-110 neurotensin Rattus norvegicus 73-84 12528380-5 2002 The behavioral effects of neurotensin in operated rats are connected with normalization of motivational and emotional states of animals and may be explained by recovery of interaction between the dopamine- and serotonergic systems. Dopamine 196-204 neurotensin Rattus norvegicus 26-37 12528380-6 2002 It is suggested that the mechanisms of this normalizing effects of neurotensin at the levels of the caudate nucleus and substantia nigra are different and are associated preferentially with its action either on dopamine- or serotonergic structures. Dopamine 211-219 neurotensin Rattus norvegicus 67-78 12070755-0 2002 The neurotensin receptor antagonist SR 142948A blocks the efflux of dopamine evoked in nucleus accumbens by neurotensin ejection into the ventral tegmental area. Dopamine 68-76 neurotensin Rattus norvegicus 4-15 12111825-1 2002 The neuroanatomical and functional relationships between dopamine (DA) and neurotensin (NT) and DA and neuropeptide Y (NPY) suggest a role for these neuropeptides in DA-related neuropsychiatric disorders. Dopamine 57-65 neurotensin Rattus norvegicus 75-86 12111825-1 2002 The neuroanatomical and functional relationships between dopamine (DA) and neurotensin (NT) and DA and neuropeptide Y (NPY) suggest a role for these neuropeptides in DA-related neuropsychiatric disorders. Dopamine 67-69 neurotensin Rattus norvegicus 75-86 12126877-0 2002 A 6-hydroxydopamine lesion of the mesostriatal dopamine system decreases the expression of corticotropin releasing hormone and neurotensin mRNAs in the amygdala and bed nucleus of the stria terminalis. Dopamine 11-19 neurotensin Rattus norvegicus 127-138 12126877-11 2002 This study provides evidence that the mesostriatal DA system regulates CRH and neurotensin mRNA in the BSTov and CEA, suggesting that dopamine may be an important modulator of CRH and neurotensin function within these nuclei. Dopamine 134-142 neurotensin Rattus norvegicus 79-90 12126877-11 2002 This study provides evidence that the mesostriatal DA system regulates CRH and neurotensin mRNA in the BSTov and CEA, suggesting that dopamine may be an important modulator of CRH and neurotensin function within these nuclei. Dopamine 134-142 neurotensin Rattus norvegicus 184-195 12126877-12 2002 Although the precise mechanisms are not clear, and the involvement of noradrenergic systems cannot be precluded, data are consistent with the idea that dopamine, released in response to a stressful experience for example, interacts with CRH and neurotensin in the extended amygdala to affect emotional responsiveness. Dopamine 152-160 neurotensin Rattus norvegicus 245-256 12070755-0 2002 The neurotensin receptor antagonist SR 142948A blocks the efflux of dopamine evoked in nucleus accumbens by neurotensin ejection into the ventral tegmental area. Dopamine 68-76 neurotensin Rattus norvegicus 108-119 11413237-0 2001 Endogenous neurotensin down-regulates dopamine efflux in the nucleus accumbens as revealed by SR-142948A, a selective neurotensin receptor antagonist. Dopamine 38-46 neurotensin Rattus norvegicus 11-22 11809861-3 2002 By contrast, D1 agonists induce contralateral turning and augment neurotensin mRNA levels in dopamine-depleted striatum. Dopamine 93-101 neurotensin Rattus norvegicus 66-77 11809861-7 2002 In situ hybridization showed that LEK-8829 induced the expression of neurotensin and ania-4 mRNAs in dopamine-intact striatum that could be completely blocked only by the combined treatment with SCH-23390 and quinpirole. Dopamine 101-109 neurotensin Rattus norvegicus 69-80 11955721-1 2002 Dopamine-containing neurones of the ventral tegmental area express neurotensin receptors which are involved in regulating cell firing and dopamine release. Dopamine 0-8 neurotensin Rattus norvegicus 67-78 11955721-1 2002 Dopamine-containing neurones of the ventral tegmental area express neurotensin receptors which are involved in regulating cell firing and dopamine release. Dopamine 138-146 neurotensin Rattus norvegicus 67-78 11955721-2 2002 Although indirect evidence suggests that some neurotensin receptors may be localised on the nerve terminals of dopaminergic neurones in the striatum and thus locally regulate dopamine release, a clear demonstration of such a mechanism is lacking and a number of indirect sites of action are possible. Dopamine 111-119 neurotensin Rattus norvegicus 46-57 11413237-0 2001 Endogenous neurotensin down-regulates dopamine efflux in the nucleus accumbens as revealed by SR-142948A, a selective neurotensin receptor antagonist. Dopamine 38-46 neurotensin Rattus norvegicus 118-129 11413237-2 2001 It was used to investigate the role of endogenous neurotensin in the regulation of dopamine efflux in the nucleus accumbens and striatum of anaesthetized and pargyline-treated rats. Dopamine 83-91 neurotensin Rattus norvegicus 50-61 11413237-12 2001 These results strengthen the hypothesis that endogenous neurotensin could exert a negative control on mesolimbic dopamine efflux. Dopamine 113-121 neurotensin Rattus norvegicus 56-67 10658621-2 2000 The neurotensin fragment (8-13) induced comparable increases in firing rate of the substantia nigra and ventral tegmental area dopamine neurons (EC50 values 30 and 45 nM, respectively). Dopamine 127-135 neurotensin Rattus norvegicus 4-15 11471555-0 2001 In vivo gene transfer to dopamine neurons of rat substantia nigra via the high-affinity neurotensin receptor. Dopamine 25-33 neurotensin Rattus norvegicus 88-99 10658621-0 2000 Neurotensin attenuates the quinpirole-induced inhibition of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area. Dopamine 79-87 neurotensin Rattus norvegicus 0-11 10658621-1 2000 In the present study we describe the excitatory effects of the bioactive peptide neurotensin on the electrical activity of dopamine neurons (simultaneously recorded) in the substantia nigra pars compacta and the ventral tegmental area. Dopamine 123-131 neurotensin Rattus norvegicus 81-92 11297813-1 2001 Neurotensin interacts with central dopamine systems and has been suggested to exert antipsychotic drug-like actions. Dopamine 35-43 neurotensin Rattus norvegicus 0-11 10973609-0 2000 Effects of prefrontal cortex microinjection of neurotensin-(8-13) on midbrain dopamine and non-dopamine cell firing. Dopamine 78-86 neurotensin Rattus norvegicus 47-58 10973609-0 2000 Effects of prefrontal cortex microinjection of neurotensin-(8-13) on midbrain dopamine and non-dopamine cell firing. Dopamine 95-103 neurotensin Rattus norvegicus 47-58 10973609-1 2000 Effects of prefrontal cortex microinjections of 0.3 and 3 nmol/0.5 microl of neurotensin-(8-13) on the firing rate of midbrain dopamine and non-dopamine cells were studied in urethane-anesthetized rats. Dopamine 127-135 neurotensin Rattus norvegicus 77-88 10973609-2 2000 Neurotensin produced an increase in firing in 14 of 26 dopamine cells tested, an effect that peaked between 15 and 20 min after the injection at both doses. Dopamine 55-63 neurotensin Rattus norvegicus 0-11 10973609-3 2000 On the other hand, a majority of non-dopamine cells (7/10) tested with the higher dose of neurotensin showed a statistically significant decrease in firing when compared to saline, an effect that also peaked between 15 and 20 min. Dopamine 37-45 neurotensin Rattus norvegicus 90-101 10973609-4 2000 These results show that prefrontal cortex neurotensin can modulate both dopamine and non-dopamine neurotransmission in the ventral midbrain. Dopamine 72-80 neurotensin Rattus norvegicus 42-53 10973609-4 2000 These results show that prefrontal cortex neurotensin can modulate both dopamine and non-dopamine neurotransmission in the ventral midbrain. Dopamine 89-97 neurotensin Rattus norvegicus 42-53 10103090-2 1999 Using non-peptide neurotensin receptor antagonists, including SR48692, we have determined that blockade of neurotensin receptors reduced the cooperative responses of direct acting D2-like (quinpirole) and partial D1-like (SKF38393) dopamine agonists on the expression of Fos-like antigens and zif268 mRNA. Dopamine 232-240 neurotensin Rattus norvegicus 107-118 10869842-1 2000 Ejections of 10(-5)-10(-3)M neurotensin into the ventral tegmental area increased dopamine efflux measured by electrochemical approaches in the prefrontal cortex of anaesthetized rats. Dopamine 82-90 neurotensin Rattus norvegicus 28-39 10869842-2 2000 In the same conditions, the effects evoked on dopamine efflux by 10(-5)M neurotensin(8-13) and [D-Tyr(11)]neurotensin were different from each other and depended on the explored area: the prefrontal cortex and the caudal and rostral nucleus accumbens. Dopamine 46-54 neurotensin Rattus norvegicus 73-84 10869842-2 2000 In the same conditions, the effects evoked on dopamine efflux by 10(-5)M neurotensin(8-13) and [D-Tyr(11)]neurotensin were different from each other and depended on the explored area: the prefrontal cortex and the caudal and rostral nucleus accumbens. Dopamine 46-54 neurotensin Rattus norvegicus 106-117 9786410-8 1998 It is suggested that some of the reported anti-dopaminergic behavioral effects of basal ganglia neurotensin may be attenuated in conditions of reduced dopamine neurotransmission. Dopamine 47-55 neurotensin Rattus norvegicus 96-107 9681955-0 1998 Differential effects of neurotensin on dopamine release in the caudal and rostral nucleus accumbens: a combined in vivo electrochemical and electrophysiological study. Dopamine 39-47 neurotensin Rattus norvegicus 24-35 9681955-1 1998 The time-course of variations in extracellular dopamine concentration following local pressure ejection of 10(-7) to 10(-3) M neurotensin into the ventral tegmental area of the rat was determined in the minute range in the nucleus accumbens by means of differential normal pulse voltammetry associated with carbon fibre electrodes. Dopamine 47-55 neurotensin Rattus norvegicus 126-137 9705573-0 1998 Pharmacological evidence that neurotensin mediates prolactin-induced activation of tuberoinfundibular dopamine neurons. Dopamine 102-110 neurotensin Rattus norvegicus 30-41 9681955-3 1998 The lowest concentration of neurotensin (10(-7) M) enhanced the extracellular dopamine concentration throughout the nucleus accumbens and stimulated the discharge activity of ventral tegmental area dopaminergic neurons. Dopamine 78-86 neurotensin Rattus norvegicus 28-39 9705573-1 1998 The purpose of this study was to investigate the role of neurotensin (NT) receptors in mediating the stimulatory effects of prolactin on the activity of tuberoinfundibular dopamine (TIDA) neurons in male and female rats. Dopamine 172-180 neurotensin Rattus norvegicus 57-68 9681955-4 1998 The two highest concentrations of neurotensin (10(-5) M and 10(-3) M) evoked two patterns of responses on the extracellular dopamine concentration and on the discharge activity of dopaminergic neurons. Dopamine 124-132 neurotensin Rattus norvegicus 34-45 9681955-10 1998 These results suggest that variations in extracellular dopamine concentration evoked by neurotensin administration into the ventral tegmental area are the result of neurotensin-evoked changes in dopaminergic activity. Dopamine 55-63 neurotensin Rattus norvegicus 88-99 9681955-10 1998 These results suggest that variations in extracellular dopamine concentration evoked by neurotensin administration into the ventral tegmental area are the result of neurotensin-evoked changes in dopaminergic activity. Dopamine 55-63 neurotensin Rattus norvegicus 165-176 9392852-1 1997 Neurotensin is a neuropeptide which coexists with mesolimbic dopamine and has exhibited neuroleptic-like activity in the nucleus accumbens. Dopamine 61-69 neurotensin Rattus norvegicus 0-11 9458896-3 1998 Direct injection of neurotensin into the nucleus accumbens (NACB), part of the mesolimbic dopamine system, reduces gastric mucosal injury, suggesting that neurotensin confers protection on the mucosa through interaction with the mesolimbic system. Dopamine 90-98 neurotensin Rattus norvegicus 20-31 9324135-2 1997 Administration of neurotensin into the lateral ventricle or into the nucleus accumbens, one of the mesolimbic dopamine system nuclei, is associated with protection when given before exposure to cold water restraint. Dopamine 110-118 neurotensin Rattus norvegicus 18-29 9324135-4 1997 In addition, pretreatment with 6-hydroxy dopamine into the mesolimbic nuclei, which depletes them of endogenous dopamine, prior to exposure to cold water restraint, ameliorates the protective effect of central neurotensin. Dopamine 41-49 neurotensin Rattus norvegicus 210-221 9324135-7 1997 Taken together, these observations support the hypothesis that centrally administered neurotensin, particularly into the nuclei of the mesolimbic dopamine system, confers protection against gastric mucosal injury produced by 2 hours of cold water restraint. Dopamine 146-154 neurotensin Rattus norvegicus 86-97 9280158-1 1997 Midbrain dopaminergic neurons are excited by neurotensin (NT) and inhibited by dopamine. Dopamine 9-17 neurotensin Rattus norvegicus 45-56 9280158-1 1997 Midbrain dopaminergic neurons are excited by neurotensin (NT) and inhibited by dopamine. Dopamine 9-17 neurotensin Rattus norvegicus 58-60 9215596-0 1997 Involvement of cortical neurotensin in the regulation of rat meso-cortico-limbic dopamine neurons: evidence from changes in the number of spontaneously active A10 cells after neurotensin receptor blockade. Dopamine 81-89 neurotensin Rattus norvegicus 24-35 9237521-1 1997 Neurotensin is a neuropeptide which coexists with mesolimbic dopamine. Dopamine 61-69 neurotensin Rattus norvegicus 0-11 9237521-2 1997 Previous studies have shown that centrally administered neurotensin can modulate the activity of mesolimbic dopamine with a profile similar to neuroleptics. Dopamine 108-116 neurotensin Rattus norvegicus 56-67 8841909-1 1996 The neuroleptic-like effects of neurotensin (NT) are thought to be due to interactions with dopamine (DA) acting primarily at D2 receptors within the nucleus accumbens septi (Acb). Dopamine 92-100 neurotensin Rattus norvegicus 32-43 8884776-0 1996 Morphologically distinct subpopulations of neurotensin-immunoreactive striatal neurons observed in rat following dopamine depletions and D2 receptor blockade project to the globus pallidus. Dopamine 113-121 neurotensin Rattus norvegicus 43-54 8884776-1 1996 It has been reported in previous studies that perikaryal neurotensin immunoreactivity is largely absent in the rat striatum except following striatal dopamine depletion or blockade of dopamine D2 receptors, after which, however, neurotensin immunoreactivity is elicited in at least two distinct subpopulations of striatal neurons [Zahm D.S. Dopamine 150-158 neurotensin Rattus norvegicus 57-68 8841909-1 1996 The neuroleptic-like effects of neurotensin (NT) are thought to be due to interactions with dopamine (DA) acting primarily at D2 receptors within the nucleus accumbens septi (Acb). Dopamine 102-104 neurotensin Rattus norvegicus 32-43 7722490-12 1995 In conclusion, these findings suggest that endogenous neurotensin may attenuate the facilitation of D2 receptor blockade on mesolimbic but not nigrostriatal dopamine transmission. Dopamine 157-165 neurotensin Rattus norvegicus 54-65 7477962-11 1995 These results indicate that neurotensin is internalized throughout the terminal and dendritic arborization of mesostriatal dopamine cells and that the internalized peptide is transported centripetally from both locations to the soma of the cells. Dopamine 123-131 neurotensin Rattus norvegicus 28-39 7722490-0 1995 Blockade of neurotensin receptor by SR 48692 potentiates the facilitatory effect of haloperidol on the evoked in vivo dopamine release in the rat nucleus accumbens. Dopamine 118-126 neurotensin Rattus norvegicus 12-23 7746351-1 1995 Microinjection of neurotensin(1-13) or neurotensin(8-13) into the ventral tegmental area (VTA) of anaesthetized rats produced dose-dependent (1-100 pg) dopamine release in the nucleus accumbens as measured by differential pulse amperometry (DPA). Dopamine 152-160 neurotensin Rattus norvegicus 18-29 8808171-2 1995 When administered centrally, neurotensin induces various effects and modulates the activity of the mesolimbic dopamine system. Dopamine 110-118 neurotensin Rattus norvegicus 29-40 8808171-10 1995 As direct and indirect dopamine agonists have been reported to promote neurotensin release in the cortex, behavioural studies were performed using injection of apomorphine. Dopamine 23-31 neurotensin Rattus norvegicus 71-82 7746351-1 1995 Microinjection of neurotensin(1-13) or neurotensin(8-13) into the ventral tegmental area (VTA) of anaesthetized rats produced dose-dependent (1-100 pg) dopamine release in the nucleus accumbens as measured by differential pulse amperometry (DPA). Dopamine 152-160 neurotensin Rattus norvegicus 39-50 7819533-3 1994 The results demonstrate a stronger reduction in the affinity of DA for neostriatal D2 receptors by the NT/NN peptides in brain sections compared with membrane preparations indicating the possible involvement of cytoplasmic factors and/or a demand for a more intact membrane structure in these receptor-receptor interactions. Dopamine 64-66 neurotensin Rattus norvegicus 103-105 7716073-4 1995 In vivo, SR 48692 antagonized the increase in rat brain mesolimbic dopamine turnover induced by the systemically active neurotensin peptide, EI [(N-Me)Arg-Lys-Pro-Trp-tert-Leu-Leu]. Dopamine 67-75 neurotensin Rattus norvegicus 120-131 7862953-1 1994 One major mechanism underlying the central action of neurotensin is an interaction with the function of dopamine (DA)-containing neurons. Dopamine 104-112 neurotensin Rattus norvegicus 53-64 7862953-1 1994 One major mechanism underlying the central action of neurotensin is an interaction with the function of dopamine (DA)-containing neurons. Dopamine 114-116 neurotensin Rattus norvegicus 53-64 7936192-0 1994 Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. Dopamine 78-86 neurotensin Rattus norvegicus 32-43 7936192-1 1994 The main aim of the present study was to investigate the effects of local perfusion with the tridecapeptide neurotensin on extracellular GABA and dopamine levels in the nucleus accumbens of the halothane-anaesthetized rat, using in vivo microdialysis. Dopamine 146-154 neurotensin Rattus norvegicus 108-119 7936192-7 1994 Towards this aim, the effects of local perfusion with a high 1 microM concentration of neurotensin into the nucleus accumbens increased both GABA (210% of basal value) and dopamine (145% of basal) release. Dopamine 172-180 neurotensin Rattus norvegicus 87-98 7936192-8 1994 However, a low (10 nM) concentration of neurotensin again increased GABA release (160% of basal), but decreased that of dopamine (75% of basal value). Dopamine 120-128 neurotensin Rattus norvegicus 40-51 7936192-9 1994 Furthermore, the local perfusion with the GABAA receptor antagonist bicuculline abolished the neurotensin (10 nM) induced inhibition of dopamine release without affecting the increase in GABA release. Dopamine 136-144 neurotensin Rattus norvegicus 94-105 7936192-10 1994 These findings suggest that neurotensin modulates both GABA and dopamine neurotransmission in the nucleus accumbens. Dopamine 64-72 neurotensin Rattus norvegicus 28-39 8301574-1 1994 The present study was designed to compare, with respect to structure-activity relationships, the receptors that subserve the hypothermic and analgesic effects of neurotensin (NT) to the receptor that mediates the effects of NT in mesencephalic dopamine (DA) neurons, and to compare these receptors to the cloned adult rat brain NT receptor and to newborn mouse and rat brain NT receptors. Dopamine 254-256 neurotensin Rattus norvegicus 162-173 8182549-1 1994 Large increases of neurotensin (NT)-like immunoreactivity in the rat neostriatum have been reported previously after treatment with either dopamine D2 receptor antagonists (e.g., haloperidol) or potent indirect dopamine agonists (e.g., methamphetamine). Dopamine 139-147 neurotensin Rattus norvegicus 19-30 8182549-1 1994 Large increases of neurotensin (NT)-like immunoreactivity in the rat neostriatum have been reported previously after treatment with either dopamine D2 receptor antagonists (e.g., haloperidol) or potent indirect dopamine agonists (e.g., methamphetamine). Dopamine 139-147 neurotensin Rattus norvegicus 32-34 8200423-0 1994 SR 48692 inhibits neurotensin-induced [3H]dopamine release in rat striatal slices and mesencephalic cultures. Dopamine 42-50 neurotensin Rattus norvegicus 18-29 8200423-2 1994 SR 48692 (100 nM) also suppressed the neurotensin (10 nM)-induced increase (47%) in K(+)-evoked [3H]dopamine release in primary cultures of fetal rat mesencephalic cells. Dopamine 100-108 neurotensin Rattus norvegicus 38-49 8014889-3 1994 In principal cells, which are presumed to contain dopamine, neurotensin (< or = 1 microM) caused an inward current at -60 mV in thirty of forty-seven neurones and had no effect on the remainder. Dopamine 50-58 neurotensin Rattus norvegicus 60-71 8058127-6 1994 Using high pressure liquid chromatography with electrochemical detection, we showed that microgram amounts of neurotensin injected into the ventral tegmental area increased dihydroxyphenylacetate/dopamine ratios in the nucleus accumbens. Dopamine 196-204 neurotensin Rattus norvegicus 110-121 8058127-7 1994 Using in vivo voltammetry techniques, we found that the injection of nanogram and picogram amounts of neurotensin in the ventral tegmental area stimulated dopamine efflux in the nucleus accumbens. Dopamine 155-163 neurotensin Rattus norvegicus 102-113 8058127-9 1994 These results indicate complex interactions between neurotensin and the mesolimbic dopamine system. Dopamine 83-91 neurotensin Rattus norvegicus 52-63 8101133-9 1993 These findings indicate that, using field stimulation when dopaminergic, cholinergic and NT-containing neurons are stimulated in concert, NT is capable of releasing both ACh and DA in the striatum, but its effect on ACh release is masked unless the D2 receptor-mediated tonic inhibitory effect of DA released from the nigro-striatal pathway is attenuated. Dopamine 178-180 neurotensin Rattus norvegicus 138-140 8242350-2 1993 Neurotensin injected into the VTA produces motor stimulation and release of dopamine in the nucleus accumbens. Dopamine 76-84 neurotensin Rattus norvegicus 0-11 8105419-13 1993 These results together with evidence from the literature suggest that methamphetamine induced a massive release of dopamine from nigral dendrites acting on presynaptic D1 dopamine receptors located on neurotensinergic terminals leading to a marked increase in neurotensin-like immunoreactivity in the pars reticulata. Dopamine 115-123 neurotensin Rattus norvegicus 201-212 8332255-1 1993 Interactions between dopamine and neurotensin or dopamine and cholecystokinin have been demonstrated in the basal ganglia. Dopamine 21-29 neurotensin Rattus norvegicus 34-45 8101133-1 1993 The effect of neurotensin (NT) on the release of acetylcholine (ACh) and dopamine (DA) from striatal slices of the rat brain was studied. Dopamine 73-81 neurotensin Rattus norvegicus 14-25 8101133-1 1993 The effect of neurotensin (NT) on the release of acetylcholine (ACh) and dopamine (DA) from striatal slices of the rat brain was studied. Dopamine 73-81 neurotensin Rattus norvegicus 27-29 8101133-9 1993 These findings indicate that, using field stimulation when dopaminergic, cholinergic and NT-containing neurons are stimulated in concert, NT is capable of releasing both ACh and DA in the striatum, but its effect on ACh release is masked unless the D2 receptor-mediated tonic inhibitory effect of DA released from the nigro-striatal pathway is attenuated. Dopamine 297-299 neurotensin Rattus norvegicus 89-91 8101133-1 1993 The effect of neurotensin (NT) on the release of acetylcholine (ACh) and dopamine (DA) from striatal slices of the rat brain was studied. Dopamine 83-85 neurotensin Rattus norvegicus 14-25 8101133-1 1993 The effect of neurotensin (NT) on the release of acetylcholine (ACh) and dopamine (DA) from striatal slices of the rat brain was studied. Dopamine 83-85 neurotensin Rattus norvegicus 27-29 8101133-9 1993 These findings indicate that, using field stimulation when dopaminergic, cholinergic and NT-containing neurons are stimulated in concert, NT is capable of releasing both ACh and DA in the striatum, but its effect on ACh release is masked unless the D2 receptor-mediated tonic inhibitory effect of DA released from the nigro-striatal pathway is attenuated. Dopamine 297-299 neurotensin Rattus norvegicus 138-140 8486330-0 1993 Neurotensin modulates differently potassium, veratridine and 4-aminopyridine-evoked release of dopamine in rat striatal slices. Dopamine 95-103 neurotensin Rattus norvegicus 0-11 8422898-0 1993 Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum. Dopamine 68-76 neurotensin Rattus norvegicus 0-11 8422898-2 1993 Neurotensin (1 nM) plus CCK-8 (1 nM) effectively counteracted the apomorphine-induced inhibition of neostriatal perfusate levels of dopamine (DA). Dopamine 132-140 neurotensin Rattus norvegicus 0-11 8422898-2 1993 Neurotensin (1 nM) plus CCK-8 (1 nM) effectively counteracted the apomorphine-induced inhibition of neostriatal perfusate levels of dopamine (DA). Dopamine 142-144 neurotensin Rattus norvegicus 0-11 1407692-4 1992 Methylphenidate increased both dopamine and neurotensin (226 +/- 26% and 151 +/- 14% of basal respectively) co-synchronously, suggesting exocytosis of vesicles containing both dopamine and neurotensin. Dopamine 176-184 neurotensin Rattus norvegicus 44-55 1330370-3 1992 By the third postnatal day, a dense dopamine projection from neurons in the dorsal tier of the mesostriatal group innervates non-patch areas of the striatum, i.e. the matrix, and is followed by the appearance there of neurotensin, somatostatin and calcium binding protein. Dopamine 36-44 neurotensin Rattus norvegicus 218-229 1436486-0 1992 Pharmacological evidence for common mechanisms underlying the effects of neurotensin and neuroleptics on in vivo dopamine efflux in the rat nucleus accumbens. Dopamine 113-121 neurotensin Rattus norvegicus 73-84 1436486-2 1992 Both neurotensin and haloperidol administration elicited an immediate increase in dopamine efflux in the nucleus accumbens. Dopamine 82-90 neurotensin Rattus norvegicus 5-16 1436486-3 1992 Gamma-hydroxybutyric acid lactone, an agent known to block impulse flow in dopamine neurons, either prevented when given before neurotensin or reversed neurotensin-induced increases in accumbens dopamine efflux. Dopamine 75-83 neurotensin Rattus norvegicus 152-163 1436404-0 1992 Neurotensin increases extracellular striatal dopamine levels in vivo. Dopamine 45-53 neurotensin Rattus norvegicus 0-11 1436404-1 1992 This study employed intracranial microdialysis to assess the effects of neurotensin (NT) infusion on extracellular dopamine (DA) and DA metabolite concentrations in the rat striatum and nucleus accumbens, and the effects of NT on alterations in extracellular DA levels induced by cocaine and the DA D-2 receptor agonist, quinpirole. Dopamine 115-123 neurotensin Rattus norvegicus 72-83 1436404-1 1992 This study employed intracranial microdialysis to assess the effects of neurotensin (NT) infusion on extracellular dopamine (DA) and DA metabolite concentrations in the rat striatum and nucleus accumbens, and the effects of NT on alterations in extracellular DA levels induced by cocaine and the DA D-2 receptor agonist, quinpirole. Dopamine 133-135 neurotensin Rattus norvegicus 72-83 1436404-1 1992 This study employed intracranial microdialysis to assess the effects of neurotensin (NT) infusion on extracellular dopamine (DA) and DA metabolite concentrations in the rat striatum and nucleus accumbens, and the effects of NT on alterations in extracellular DA levels induced by cocaine and the DA D-2 receptor agonist, quinpirole. Dopamine 133-135 neurotensin Rattus norvegicus 72-83 1436486-3 1992 Gamma-hydroxybutyric acid lactone, an agent known to block impulse flow in dopamine neurons, either prevented when given before neurotensin or reversed neurotensin-induced increases in accumbens dopamine efflux. Dopamine 195-203 neurotensin Rattus norvegicus 152-163 1436486-5 1992 The dopamine receptor agonist apomorphine reversed neurotensin- and haloperidol-induced increases in dopamine efflux. Dopamine 4-12 neurotensin Rattus norvegicus 51-62 1436486-6 1992 Amphetamine, administered during the peak dopamine stimulatory effects induced by neurotensin or haloperidol, resulted in increases above baseline which were significantly greater than the effects of amphetamine alone. Dopamine 42-50 neurotensin Rattus norvegicus 82-93 1436486-8 1992 These in vivo results suggest that neurotensin and haloperidol may augment dopamine efflux in the nucleus accumbens via common mechanisms of action which may involve activation of mesotelencephalic dopamine neuronal firing. Dopamine 75-83 neurotensin Rattus norvegicus 35-46 1436486-8 1992 These in vivo results suggest that neurotensin and haloperidol may augment dopamine efflux in the nucleus accumbens via common mechanisms of action which may involve activation of mesotelencephalic dopamine neuronal firing. Dopamine 198-206 neurotensin Rattus norvegicus 35-46 1407692-7 1992 Moreover, dopamine may act presynaptically to increase neurotensin release and the different behavioral profiles of these psychostimulants may in part relate to their different effects on neurotensin release. Dopamine 10-18 neurotensin Rattus norvegicus 55-66 1318960-0 1992 Roles of intracellular cAMP and protein kinase A in the actions of dopamine and neurotensin on midbrain dopamine neurons. Dopamine 104-112 neurotensin Rattus norvegicus 80-91 1319909-2 1992 Neurotensin lowered the stimulation frequency required to sustain threshold levels of responding for brain stimulation reward, suggesting that this neuropeptide is involved in modulating the activity of dopamine neurons that mediate behaviors motivated by positive reinforces. Dopamine 203-211 neurotensin Rattus norvegicus 0-11 1523160-0 1992 Balance of glutamate and dopamine in the nucleus accumbens modulates self-stimulation behavior after injection of cholecystokinin and neurotensin in the rat brain. Dopamine 25-33 neurotensin Rattus norvegicus 134-145 1523160-1 1992 Subpopulations of dopamine (DA) neurons in the ventral mesencephalon have been reported to contain cholecystokinin (CCK) and neurotensin (NT), giving rise to DA, DA/NT, NT/CCK and DA/CCK/NT projections. Dopamine 18-26 neurotensin Rattus norvegicus 125-136 1523160-1 1992 Subpopulations of dopamine (DA) neurons in the ventral mesencephalon have been reported to contain cholecystokinin (CCK) and neurotensin (NT), giving rise to DA, DA/NT, NT/CCK and DA/CCK/NT projections. Dopamine 28-30 neurotensin Rattus norvegicus 125-136 1348274-5 1992 In the mesencephalic cultures, NT increased potassium-evoked release of tritiated dopamine, and the relative potencies of various NT-related peptides to increase dopamine release were in good agreement with their abilities to bind to NT sites. Dopamine 82-90 neurotensin Rattus norvegicus 31-33 1348274-5 1992 In the mesencephalic cultures, NT increased potassium-evoked release of tritiated dopamine, and the relative potencies of various NT-related peptides to increase dopamine release were in good agreement with their abilities to bind to NT sites. Dopamine 162-170 neurotensin Rattus norvegicus 130-132 1348274-5 1992 In the mesencephalic cultures, NT increased potassium-evoked release of tritiated dopamine, and the relative potencies of various NT-related peptides to increase dopamine release were in good agreement with their abilities to bind to NT sites. Dopamine 162-170 neurotensin Rattus norvegicus 130-132 1319909-5 1992 Subsequent injection of morphine (2.5-5 micrograms/0.5 microliter) into the same site produced a weaker facilitation of brain stimulation reward than expected, suggesting that local damage after multiple central injections or prior injections of neurotensin itself reduced the responsiveness of dopamine neurons to opiates. Dopamine 295-303 neurotensin Rattus norvegicus 246-257 1319909-6 1992 Taken together, the results are consistent with data indicating that activation of neurotensin receptors in the ventral mesencephalon stimulates dopamine cell firing and axonal dopamine release in limbic terminal fields and suggest that endogenous neurotensin is involved in the control of behavior motivated by positive reinforcement. Dopamine 145-153 neurotensin Rattus norvegicus 83-94 1319909-6 1992 Taken together, the results are consistent with data indicating that activation of neurotensin receptors in the ventral mesencephalon stimulates dopamine cell firing and axonal dopamine release in limbic terminal fields and suggest that endogenous neurotensin is involved in the control of behavior motivated by positive reinforcement. Dopamine 177-185 neurotensin Rattus norvegicus 83-94 1542410-0 1992 Subsets of neurotensin-immunoreactive neurons revealed following antagonism of the dopamine-mediated suppression of neurotensin immunoreactivity in the rat striatum. Dopamine 83-91 neurotensin Rattus norvegicus 11-22 1361112-0 1992 Morphological substrate for neurotensin-dopamine interactions in the rat midbrain tegmentum. Dopamine 40-48 neurotensin Rattus norvegicus 28-39 1593929-4 1992 These results suggest that neurotensin-induced inhibition of secretion of prolactin and alpha MSH from the pituitary may be due to the stimulatory action of this neuropeptide on the release of dopamine from tuberoinfundibular and periventricular-hypophysial neurons. Dopamine 193-201 neurotensin Rattus norvegicus 27-38 1542410-0 1992 Subsets of neurotensin-immunoreactive neurons revealed following antagonism of the dopamine-mediated suppression of neurotensin immunoreactivity in the rat striatum. Dopamine 83-91 neurotensin Rattus norvegicus 116-127 1641127-0 1992 Muscarinic antagonists attenuate neurotensin-stimulated accumbens and striatal dopamine metabolism. Dopamine 79-87 neurotensin Rattus norvegicus 33-44 1641127-12 1992 Together, the results demonstrate a functional interaction between muscarinic antagonists and neurotensin on in vivo dopamine metabolism in the nucleus accumbens and the striatum but with a greater effect in the latter region. Dopamine 117-125 neurotensin Rattus norvegicus 94-105 1365637-4 1992 The results suggest that activation of the mesolimbic dopamine system through administration of neurotensin in the ventral tegmental area produces antidepressant-like effects. Dopamine 54-62 neurotensin Rattus norvegicus 96-107 1676331-7 1991 Combined, these results suggest that NT"s effect on DA cell activity is primarily a neuromodulatory one. Dopamine 52-54 neurotensin Rattus norvegicus 37-39 1839140-1 1991 In order to better understand the neuroleptic-like effects of neurotensin in vivo, the effects of neurotensin in vitro on dopamine D2 and D1 agonist and antagonist binding sites were characterized in membranes from the neostriatum and the subcortical limbic area. Dopamine 122-130 neurotensin Rattus norvegicus 98-109 1839140-5 1991 Neurotensin increased the KH of dopamine vs [3H]raclopride binding and, in the presence of GTP, also KL. Dopamine 32-40 neurotensin Rattus norvegicus 0-11 1839140-9 1991 This antagonistic intramembrane interaction may underlie the neuroleptic-like effects of neurotensin at low concentrations in vivo on D2 agonist binding, dopamine release, and on D2-mediated behaviours. Dopamine 154-162 neurotensin Rattus norvegicus 89-100 1686786-13 1991 Release of neurotensin and catecholamines, most likely dopamine, from the same or separate terminals on common targets in the CNA may account for certain similarities in their stress-related functions. Dopamine 55-63 neurotensin Rattus norvegicus 11-22 1907216-1 1991 The extent of neurotensin (NT) colocalization in the different dopamine (DA) terminal fields of the rat cerebral cortex has been investigated and compared to previous data obtained in man (Gaspar et al., J. Comp. Dopamine 73-75 neurotensin Rattus norvegicus 14-25 1350070-5 1992 When dopamine and neurotensin were concomitantly applied, the magnitude of maximal inhibitions induced by dopamine was modified in the majority of neurons tested. Dopamine 106-114 neurotensin Rattus norvegicus 18-29 1350070-9 1992 In the anterior cingulate cortex, inhibitions, respectively, induced by the dopamine D1 agonist, SKF 38393, and the D2 agonist, LY 171555, were also decreased by simultaneous application of neurotensin. Dopamine 76-84 neurotensin Rattus norvegicus 190-201 1350070-10 1992 Together with currently available data on the cellular localization of neurotensin receptors in rat brain, these results suggest that the modulation of dopamine inhibition by neurotensin may have opposite effects depending on whether the neurotensin receptors are located postsynaptically on target neurons (antagonistic effects) or presynaptically on dopamine terminals (potentiating effects). Dopamine 152-160 neurotensin Rattus norvegicus 175-186 1350070-10 1992 Together with currently available data on the cellular localization of neurotensin receptors in rat brain, these results suggest that the modulation of dopamine inhibition by neurotensin may have opposite effects depending on whether the neurotensin receptors are located postsynaptically on target neurons (antagonistic effects) or presynaptically on dopamine terminals (potentiating effects). Dopamine 152-160 neurotensin Rattus norvegicus 175-186 1350070-10 1992 Together with currently available data on the cellular localization of neurotensin receptors in rat brain, these results suggest that the modulation of dopamine inhibition by neurotensin may have opposite effects depending on whether the neurotensin receptors are located postsynaptically on target neurons (antagonistic effects) or presynaptically on dopamine terminals (potentiating effects). Dopamine 352-360 neurotensin Rattus norvegicus 175-186 1350070-10 1992 Together with currently available data on the cellular localization of neurotensin receptors in rat brain, these results suggest that the modulation of dopamine inhibition by neurotensin may have opposite effects depending on whether the neurotensin receptors are located postsynaptically on target neurons (antagonistic effects) or presynaptically on dopamine terminals (potentiating effects). Dopamine 352-360 neurotensin Rattus norvegicus 175-186 1821482-1 1991 Neurotensin (NT) is a peptide colocalized with dopamine (DA) within some mesocorticolimbic DA neurons that are affected by cocaine. Dopamine 47-55 neurotensin Rattus norvegicus 0-11 1821482-1 1991 Neurotensin (NT) is a peptide colocalized with dopamine (DA) within some mesocorticolimbic DA neurons that are affected by cocaine. Dopamine 47-55 neurotensin Rattus norvegicus 13-15 1821482-1 1991 Neurotensin (NT) is a peptide colocalized with dopamine (DA) within some mesocorticolimbic DA neurons that are affected by cocaine. Dopamine 57-59 neurotensin Rattus norvegicus 0-11 1821482-1 1991 Neurotensin (NT) is a peptide colocalized with dopamine (DA) within some mesocorticolimbic DA neurons that are affected by cocaine. Dopamine 57-59 neurotensin Rattus norvegicus 13-15 1821482-11 1991 These data suggest that in central areas poor in DA uptake sites such as the PFC, NT may be a critical element in the inactivation of DA. Dopamine 49-51 neurotensin Rattus norvegicus 82-84 1821482-11 1991 These data suggest that in central areas poor in DA uptake sites such as the PFC, NT may be a critical element in the inactivation of DA. Dopamine 134-136 neurotensin Rattus norvegicus 82-84 1676331-0 1991 Neurotensin modulates autoreceptor mediated dopamine effects on midbrain dopamine cell activity. Dopamine 44-52 neurotensin Rattus norvegicus 0-11 1676331-0 1991 Neurotensin modulates autoreceptor mediated dopamine effects on midbrain dopamine cell activity. Dopamine 73-81 neurotensin Rattus norvegicus 0-11 1676331-1 1991 Interactions of neurotensin (NT) with midbrain dopamine (DA) neurons were studied in rats using microiontophoretic techniques. Dopamine 47-55 neurotensin Rattus norvegicus 16-27 1676331-8 1991 As both NT and D2 receptors in midbrain DA cell areas are primarily located on DA cells, the above results also suggest that the observed interaction between NT and DA occurred at the DA cell level. Dopamine 40-42 neurotensin Rattus norvegicus 8-10 1676331-1 1991 Interactions of neurotensin (NT) with midbrain dopamine (DA) neurons were studied in rats using microiontophoretic techniques. Dopamine 47-55 neurotensin Rattus norvegicus 29-31 1676331-4 1991 On the other hand, in these same cells, NT significantly attenuated the inhibition induced by either DA or quinpirole, a specific D2 agonist. Dopamine 101-103 neurotensin Rattus norvegicus 40-42 1676331-8 1991 As both NT and D2 receptors in midbrain DA cell areas are primarily located on DA cells, the above results also suggest that the observed interaction between NT and DA occurred at the DA cell level. Dopamine 40-42 neurotensin Rattus norvegicus 158-160 1676331-6 1991 The effect of NT appears to be selective as NT attenuated DA-induced inhibition without a measurable effect on either GABA-induced inhibition or glutamate-induced excitation of the same DA cells. Dopamine 58-60 neurotensin Rattus norvegicus 44-46 1981481-0 1990 Evidence that the stimulatory effect of neurotensin on dopamine release in rat nucleus accumbens slices is independent of dopamine D2-receptor activation. Dopamine 55-63 neurotensin Rattus norvegicus 40-51 1824779-0 1991 Neurotensin decreases the affinity of dopamine D2 agonist binding by a G protein-independent mechanism. Dopamine 38-46 neurotensin Rattus norvegicus 0-11 2046877-0 1991 Neurotensin causes a greater increase in the metabolism of dopamine in the accumbens than in the striatum in vivo. Dopamine 59-67 neurotensin Rattus norvegicus 0-11 2046877-5 1991 Neurotensin (0.1, 1.0 and 3.0 micrograms/0.5 microliter), injected into the ventral tegmental area, induced a potent and long-lasting elevation of the peak height for DOPAC in the nucleus accumbens, while the same doses in the substantia nigra produced effects on the metabolism of dopamine in the striatum of smaller amplitude and shorter duration. Dopamine 282-290 neurotensin Rattus norvegicus 0-11 2073584-2 1990 Bilateral application of neurotensin to the nucleus accumbens, like the neuroleptic haloperidol, inhibited the hyperactivity response to the dopamine agonist, n,N-propylnorapomorphine, but, unlike haloperidol, its bilateral intrastriatal application failed to reduce the degree of stereotyped behaviour induced by peripheral apomorphine injection. Dopamine 141-149 neurotensin Rattus norvegicus 25-36 2073584-6 1990 The findings of these investigations further confirm in vivo that the functional antagonism of dopamine by neurotensin is selective for the mesolimbic system, and that the effects of neurotensin can be correlated with reports on the regional distribution of its high-affinity binding sites in the rat brain. Dopamine 95-103 neurotensin Rattus norvegicus 107-118 2087439-0 1990 Involvement of dopamine in the central effect of neurotensin on intestinal motility in rats. Dopamine 15-23 neurotensin Rattus norvegicus 49-60 2147039-0 1990 Neurotensin-dopamine interactions in the substantia nigra of the rat brain. Dopamine 12-20 neurotensin Rattus norvegicus 0-11 2147039-1 1990 Single or multiple doses of the potent dopamine releaser, methamphetamine (METH), increases the content of neurotensin (NT)-like immunoreactivity (NTLI) in the substantia nigra of the rat brain by 2- to 3-fold. Dopamine 39-47 neurotensin Rattus norvegicus 107-118 1981163-3 1990 The relationship of modulation of [3H]NPA binding with neurotensin-dopamine coexistence in nerve terminals was analyzed by investigating coexistence of neurotensin and tyrosine hydroxylase (TH) immunoreactive nerve terminals in various brain areas, using a double immunohistofluorescence procedure. Dopamine 67-75 neurotensin Rattus norvegicus 55-66 1982340-0 1990 Neurotensin attenuates dopamine D2 agonist quinpirole-induced inhibition of midbrain dopamine neurons. Dopamine 23-31 neurotensin Rattus norvegicus 0-11 1982340-0 1990 Neurotensin attenuates dopamine D2 agonist quinpirole-induced inhibition of midbrain dopamine neurons. Dopamine 85-93 neurotensin Rattus norvegicus 0-11 1981163-0 1990 Intraventricular injection of neurotensin reduces dopamine D2 agonist binding in rat forebrain and intermediate lobe of the pituitary gland. Dopamine 50-58 neurotensin Rattus norvegicus 30-41 1981163-9 1990 The present study indicates that central dopamine D2 receptors may be regulated by neurotensin in vivo and that the neurotensin involved most likely is released from nerve terminals not containing dopamine, since fibers showing coexistence were only found in prefrontal and limbic cortical areas. Dopamine 41-49 neurotensin Rattus norvegicus 83-94 1697899-0 1990 Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens. Dopamine 81-89 neurotensin Rattus norvegicus 26-37 1698150-5 1990 In the presence of dopamine the stimulation of PRL release and calcium uptake due to neurotensin were abolished, and the rise in Cai was barely detectable, but neurotensin-stimulated fractional efflux persisted almost unchanged. Dopamine 19-27 neurotensin Rattus norvegicus 85-96 1698150-5 1990 In the presence of dopamine the stimulation of PRL release and calcium uptake due to neurotensin were abolished, and the rise in Cai was barely detectable, but neurotensin-stimulated fractional efflux persisted almost unchanged. Dopamine 19-27 neurotensin Rattus norvegicus 160-171 1697899-1 1990 The injection of neurotensin or the enkephalin analog Tyr-D-Ala-Gly-MePhe-Gly(ol) (DAMGO) into the A10 region of rats produces a motor stimulant effect that is associated with an increase in the postmortem levels of dopamine metabolites in the nucleus accumbens. Dopamine 216-224 neurotensin Rattus norvegicus 17-28 1697899-5 1990 Neurotensin also produced a dose-related (0.1-3.3 nmol) increase in dopamine and its metabolites. Dopamine 68-76 neurotensin Rattus norvegicus 0-11 1697899-7 1990 Following daily treatment of either neurotensin (1.0 nmol X 4 d) or DAMGO (0.03 nmol X 4 d), a significant elevation in extracellular dopamine levels occurred in the nucleus accumbens compared to an acute injection. Dopamine 134-142 neurotensin Rattus norvegicus 36-47 1701223-0 1990 Effects of neurotensin on regional brain concentrations of dopamine, serotonin and their main metabolites. Dopamine 59-67 neurotensin Rattus norvegicus 11-22 1694190-0 1990 Postnatal development of striatal neurotensin immunoreactivity in relation to clusters of substance P immunoreactive neurons and the "dopamine islands" in the rat. Dopamine 134-142 neurotensin Rattus norvegicus 34-45 1701223-3 1990 Results indicate that both doses of neurotensin significantly elevated concentrations of dopamine in the striatum and amygdala 5 min following injection. Dopamine 89-97 neurotensin Rattus norvegicus 36-47 1701223-9 1990 These findings reveal that the effects of the neurotensin on dopaminergic transmission are more widespread than previously reported in that all major dopamine pathways are affected by the peptide. Dopamine 61-69 neurotensin Rattus norvegicus 46-57 2138224-0 1990 Neurotensin-induced dopamine release in vivo and in vitro from substantia nigra and nucleus caudate. Dopamine 20-28 neurotensin Rattus norvegicus 0-11 2138224-1 1990 We compared the dopamine (DA) releasing effects of neurotensin (NT) from cell bodies (substantia nigra) and nerve terminals (nucleus caudate). Dopamine 16-24 neurotensin Rattus norvegicus 51-62 2138224-1 1990 We compared the dopamine (DA) releasing effects of neurotensin (NT) from cell bodies (substantia nigra) and nerve terminals (nucleus caudate). Dopamine 16-24 neurotensin Rattus norvegicus 64-66 2138224-1 1990 We compared the dopamine (DA) releasing effects of neurotensin (NT) from cell bodies (substantia nigra) and nerve terminals (nucleus caudate). Dopamine 26-28 neurotensin Rattus norvegicus 51-62 2138224-1 1990 We compared the dopamine (DA) releasing effects of neurotensin (NT) from cell bodies (substantia nigra) and nerve terminals (nucleus caudate). Dopamine 26-28 neurotensin Rattus norvegicus 64-66 2138224-2 1990 In rats implanted with push-pull cannula, NT induced DA release from substantia nigra and nucleus caudate. Dopamine 53-55 neurotensin Rattus norvegicus 42-44 2138224-3 1990 NT was more potent in releasing DA from the substantia nigra than from the nucleus caudate (EC50%, 1.1 microM in substantia nigra and 9.8 microM in nucleus caudate). Dopamine 32-34 neurotensin Rattus norvegicus 0-2 2138224-9 1990 A synergistic interaction on DA release was observed between NT and potassium (K+), and between NT and electrical stimulation. Dopamine 29-31 neurotensin Rattus norvegicus 61-63 2138224-9 1990 A synergistic interaction on DA release was observed between NT and potassium (K+), and between NT and electrical stimulation. Dopamine 29-31 neurotensin Rattus norvegicus 96-98 2138224-11 1990 Pretreatment of striatal slices with 15 mM K+ produced a 9-fold enhancement of NT-induced DA release. Dopamine 90-92 neurotensin Rattus norvegicus 79-81 2138224-12 1990 When K+ (25 mM, 2 min) was given together with NT there was a 2- to 3-fold increase in DA release compared to the release evoked by K+ in the absence of NT. Dopamine 87-89 neurotensin Rattus norvegicus 47-49 2549437-0 1989 Neurotensin activates tuberoinfundibular dopamine neurons and increases serum corticosterone concentrations in the rat. Dopamine 41-49 neurotensin Rattus norvegicus 0-11 2352647-2 1990 A dose-dependent augmentation of dopamine efflux as evidenced by increases in the chronoamperometric signal was observed in the nucleus accumbens following intracerebroventricular injections of neurotensin. Dopamine 33-41 neurotensin Rattus norvegicus 194-205 2352647-4 1990 The selective effects of neurotensin on mesolimbic dopamine neurons were confirmed using in vivo microdialysis. Dopamine 51-59 neurotensin Rattus norvegicus 25-36 2352647-5 1990 These results demonstrate that neurotensin can selectively enhance the release and metabolism of dopamine in neurons projecting from the ventral tegmental area to the nucleus accumbens. Dopamine 97-105 neurotensin Rattus norvegicus 31-42 2593006-0 1989 Effects of dopamine depletion on striatal neurotensin: biochemical and immunohistochemical studies. Dopamine 11-19 neurotensin Rattus norvegicus 42-53 2593006-1 1989 Interactions between striatal dopamine (DA) and neurotensin (NT) have been suggested by anatomical, behavioral, and biochemical studies. Dopamine 30-38 neurotensin Rattus norvegicus 48-59 2593006-1 1989 Interactions between striatal dopamine (DA) and neurotensin (NT) have been suggested by anatomical, behavioral, and biochemical studies. Dopamine 40-42 neurotensin Rattus norvegicus 48-59 2819469-5 1989 Neurotensin (10 nM but not 1 nM) counteracted the inhibitory effect of apomorphine on dialysate levels of dopamine without affecting those of DOPAC and HVA. Dopamine 106-114 neurotensin Rattus norvegicus 0-11 2819469-6 1989 The results indicate a facilitatory effect of neurotensin on dopamine release in rat neostriatum. Dopamine 61-69 neurotensin Rattus norvegicus 46-57 2819469-7 1989 It is suggested that activation of neurotensin receptors may cause a reduction in the affinity of dopamine autoreceptors, since the low dose of neurotensin is able to counteract the inhibitory effect of apomorphine on dopamine release. Dopamine 98-106 neurotensin Rattus norvegicus 35-46 2819469-7 1989 It is suggested that activation of neurotensin receptors may cause a reduction in the affinity of dopamine autoreceptors, since the low dose of neurotensin is able to counteract the inhibitory effect of apomorphine on dopamine release. Dopamine 98-106 neurotensin Rattus norvegicus 144-155 2819469-7 1989 It is suggested that activation of neurotensin receptors may cause a reduction in the affinity of dopamine autoreceptors, since the low dose of neurotensin is able to counteract the inhibitory effect of apomorphine on dopamine release. Dopamine 218-226 neurotensin Rattus norvegicus 35-46 2819469-7 1989 It is suggested that activation of neurotensin receptors may cause a reduction in the affinity of dopamine autoreceptors, since the low dose of neurotensin is able to counteract the inhibitory effect of apomorphine on dopamine release. Dopamine 218-226 neurotensin Rattus norvegicus 144-155 2304623-2 1990 Following stimulation of dopamine autoreceptors with either apomorphine (30 micrograms/kg, s.c.) or EMD-23448 (10 microM in the perfusion buffer) a decrease in dopamine and an increase in neurotensin release was observed. Dopamine 25-33 neurotensin Rattus norvegicus 188-199 2304623-4 1990 These data suggest that activation of dopamine autoreceptors in the prefrontal cortex produces opposing effects on the release of dopamine and neurotensin. Dopamine 38-46 neurotensin Rattus norvegicus 143-154 2819469-0 1989 Neurotensin counteracts apomorphine-induced inhibition of dopamine release as studied by microdialysis in rat neostriatum. Dopamine 58-66 neurotensin Rattus norvegicus 0-11 2819469-1 1989 Microdialysis in the neostriatum of the halothane-anesthetized male rats was used to study the effect of neurotensin on the release of dopamine and its metabolites in the absence or presence of systemic apomorphine treatment. Dopamine 135-143 neurotensin Rattus norvegicus 105-116 2819469-3 1989 Perfusion with neurotensin (1000 nM but not 10 nM) increased the dialysate levels of dopamine without affecting those of DOPAC and HVA. Dopamine 85-93 neurotensin Rattus norvegicus 15-26 2549437-9 1989 It is concluded that neurotensin acutely increases the activity of tuberoinfundibular and mesolimbic dopamine neurons and the secretion of ACTH. Dopamine 101-109 neurotensin Rattus norvegicus 21-32 3200862-9 1988 These data indicate the physiological significance of the hypothalamic inhibitory actions of neurotensin on prolactin release, which are probably mediated by its stimulation of dopamine release that in turn, inhibits prolactin secretion by the lactotropes. Dopamine 177-185 neurotensin Rattus norvegicus 93-104 20504524-2 1989 Neurotensin or its analogs were added to incubation medium of[(3)H]SCH 23390 saturation or dopamine/[(3)H]SCH 23390 inhibition experimental systems. Dopamine 91-99 neurotensin Rattus norvegicus 0-11 2480261-10 1989 In the competition related experiments, dopamine was found to displace around 70% of neurotensin binding sites in the corpus striatum and the cerebral cortex. Dopamine 40-48 neurotensin Rattus norvegicus 85-96 3386412-1 1988 The effect of neurotensin (NT) on the release of endogenous dopamine (DA) of rat striatal synaptosomes was studied. Dopamine 70-72 neurotensin Rattus norvegicus 14-25 2472151-3 1988 One such neuropeptide that is increased in concentration in dopamine terminal regions by clinically effective neuroleptic drugs is neurotensin (NT). Dopamine 60-68 neurotensin Rattus norvegicus 131-142 2472151-4 1988 Neurotensin is closely associated with dopamine neurons, as demonstrated by evidence derived from anatomic, physiologic, and pharmacologic studies. Dopamine 39-47 neurotensin Rattus norvegicus 0-11 3247254-4 1988 Assay by HPLC-EC of each perfusate showed that when the rat was sated, NT evoked a significant increase in the release of DA and DOPAC from the hypothalamus as well as augmented NE turnover, as reflected by a significant efflux in MHPG. Dopamine 122-124 neurotensin Rattus norvegicus 71-73 3247254-5 1988 However, when the rat was fasted for 22 hr, the perfusion of NT reduced DA and DOPAC concentrations in the diencephalic perfusate significantly as well as levels of both MHPG and VMA. Dopamine 72-74 neurotensin Rattus norvegicus 61-63 3150806-1 1988 A number of studies have shown that intracisternal, intracerebroventricular, or direct administration of neurotensin (NT) into the nucleus accumbens (ACC) can antagonize the arousal and excitement produced by activation of the mesolimbic dopamine (DA) system of rats. Dopamine 238-246 neurotensin Rattus norvegicus 105-116 3150806-1 1988 A number of studies have shown that intracisternal, intracerebroventricular, or direct administration of neurotensin (NT) into the nucleus accumbens (ACC) can antagonize the arousal and excitement produced by activation of the mesolimbic dopamine (DA) system of rats. Dopamine 248-250 neurotensin Rattus norvegicus 105-116 3350051-0 1988 The neurotensin analog xenopsin excites nigral dopamine neurons. Dopamine 47-55 neurotensin Rattus norvegicus 4-15 3386412-0 1988 Neurotensin potentiates the endogenous dopamine release from striatal synaptosomes of rat. Dopamine 39-47 neurotensin Rattus norvegicus 0-11 3386412-1 1988 The effect of neurotensin (NT) on the release of endogenous dopamine (DA) of rat striatal synaptosomes was studied. Dopamine 60-68 neurotensin Rattus norvegicus 14-25 3572804-4 1987 The implications of these findings to the relationship between dopamine and neurotensin transmitter systems are discussed. Dopamine 63-71 neurotensin Rattus norvegicus 76-87 2888514-0 1987 Stress-induced alterations in neurotensin, somatostatin and corticotropin-releasing factor in mesotelencephalic dopamine system regions. Dopamine 112-120 neurotensin Rattus norvegicus 30-41 2888514-1 1987 The effects of exposure to acute mild footshock stress on concentrations of neurotensin-, somatostatin-, and corticotropin-releasing factor-like immunoreactivity (li) in mesotelencephalic dopamine system regions of the rat were examined. Dopamine 188-196 neurotensin Rattus norvegicus 76-87 2888514-5 1987 These data suggest that neurotensin in the VTA may be involved in environmentally elicited activation of certain mesotelencephalic dopamine neurons. Dopamine 131-139 neurotensin Rattus norvegicus 24-35 3573983-7 1987 Addition of neurotensin (0.001 - 1.0 microM) to the bathing media produced a concentration-dependent increase in dopamine, but not serotonin, release. Dopamine 113-121 neurotensin Rattus norvegicus 12-23 3368012-0 1988 Neurotensin effects on evoked release of dopamine in slices from striatum, nucleus accumbens and prefrontal cortex in rat. Dopamine 41-49 neurotensin Rattus norvegicus 0-11 3368012-9 1988 The comparison of the effects of NT showed that in terms of efficacy, NT induced an increase in dopamine release more marked in striatum than in nucleus accumbens and prefrontal cortex. Dopamine 96-104 neurotensin Rattus norvegicus 70-72 2430058-1 1986 The present study demonstrates that 3,4-dihydroxyphenylethylamine (DA, dopamine) prevents neurotensin (NT) stimulation of both prolactin (PRL) release and calcium influx by interacting with specific receptors that are functionally linked to calcium channels. Dopamine 36-65 neurotensin Rattus norvegicus 90-101 20501123-0 1987 Effects of cholecystokinin peptides and neurotensin on dopamine release and metabolism in the rostral and caudal part of the nucleus accumbens using intracerebral dialysis in the anaesthetized rat. Dopamine 55-63 neurotensin Rattus norvegicus 40-51 20501123-1 1987 By means of intracerebral microdialysis effects of cholecystokinin peptides and neurotensin administered via the microdialysis probe have been studied on dopamine release and metabolism in the nucleus accumbens and neostriatum of the halothane anaesthetized male rat. Dopamine 154-162 neurotensin Rattus norvegicus 80-91 20501123-10 1987 accumbens perfusion with 10 ?M of neurotensin but not with any other concentration of neurotensin (0.01, 0.1, 1 and 100 ?M) increased the levels of DA in the extracellular fluid. Dopamine 148-150 neurotensin Rattus norvegicus 34-45 20501123-25 1987 accumbens these effects of neurotensin are also associated with an increase of DA metabolites, possibly suggesting that in this region neurotensin receptors may also control DA synthesis. Dopamine 79-81 neurotensin Rattus norvegicus 27-38 20501123-25 1987 accumbens these effects of neurotensin are also associated with an increase of DA metabolites, possibly suggesting that in this region neurotensin receptors may also control DA synthesis. Dopamine 79-81 neurotensin Rattus norvegicus 135-146 2430058-1 1986 The present study demonstrates that 3,4-dihydroxyphenylethylamine (DA, dopamine) prevents neurotensin (NT) stimulation of both prolactin (PRL) release and calcium influx by interacting with specific receptors that are functionally linked to calcium channels. Dopamine 67-69 neurotensin Rattus norvegicus 90-101 2430058-1 1986 The present study demonstrates that 3,4-dihydroxyphenylethylamine (DA, dopamine) prevents neurotensin (NT) stimulation of both prolactin (PRL) release and calcium influx by interacting with specific receptors that are functionally linked to calcium channels. Dopamine 71-79 neurotensin Rattus norvegicus 90-101 3792452-0 1986 Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats. Dopamine 128-136 neurotensin Rattus norvegicus 48-59 3755755-4 1986 After injection into the ventral tegmental area, NN was shown to be more potent than NT at increasing spontaneous motor activity and to produce an increase in DA metabolism in the nucleus accumbens, prefrontal cortex, diagonal band of Broca and septum. Dopamine 159-161 neurotensin Rattus norvegicus 49-51 3756495-0 1986 Involvement of brain dopamine systems on neurotensin-induced protection against stress gastric lesions. Dopamine 21-29 neurotensin Rattus norvegicus 41-52 3755755-5 1986 However, when injected into the nucleus accumbens, NN was markedly less potent than NT at inhibiting DA-induced behavioral hyperactivity. Dopamine 101-103 neurotensin Rattus norvegicus 51-53 3748452-4 1986 These results provide further evidence that NT can modulate the mesolimbic dopamine pathway. Dopamine 75-83 neurotensin Rattus norvegicus 44-46 3085873-3 1986 GRP (10(-5) M), neurotensin (NT, 10(-5) M) and DN 1417 (10(-5) M) also stimulated spontaneous release of DA and NE from the hypothalamus. Dopamine 105-107 neurotensin Rattus norvegicus 16-27 2427971-1 1986 The neuropeptides substance P, neurotensin and [Met]enkephalin are found in the ventral tegmental area, site of the A10 dopamine cell bodies. Dopamine 120-128 neurotensin Rattus norvegicus 31-42 3725825-1 1986 Several lines of evidence indicate that neurotensin may modulate the activity of dopamine systems in the central nervous system. Dopamine 81-89 neurotensin Rattus norvegicus 40-51 3725825-2 1986 The present study investigated the possibility that intraperitoneal injections of the dopamine agonists l-dopa and bromocriptine would alter the aphagia produced by central administration of neurotensin. Dopamine 86-94 neurotensin Rattus norvegicus 191-202 3485291-0 1986 Further evidence that central neurotensin inhibits pituitary prolactin secretion by stimulating dopamine release from the hypothalamus. Dopamine 96-104 neurotensin Rattus norvegicus 30-41 3713871-0 1986 Neurotensin effect on dopamine release and calcium transport in rat striatum: interactions with diphenylalkylamine calcium antagonists. Dopamine 22-30 neurotensin Rattus norvegicus 0-11 3713871-1 1986 The release of dopamine was investigated in rat striatal slices exposed in vitro to neurotensin. Dopamine 15-23 neurotensin Rattus norvegicus 84-95 3713871-3 1986 Moreover neurotensin antagonized the flunarizine-induced inhibition of K+-stimulated dopamine release. Dopamine 85-93 neurotensin Rattus norvegicus 9-20 3938838-0 1985 Behavioral and biochemical assessment of time-related changes in globus pallidus and striatal dopamine induced by intranigrally administered neurotensin. Dopamine 94-102 neurotensin Rattus norvegicus 141-152 4075132-1 1985 Many lines of evidence indicate an excitatory role by neurotensin (NT) on mesolimbic dopamine neurons in the ventral tegmental area (VTA). Dopamine 85-93 neurotensin Rattus norvegicus 54-65 2415214-0 1985 Dopamine inhibition of neurotensin-induced increase in Ca2+ influx into rat pituitary cells. Dopamine 0-8 neurotensin Rattus norvegicus 23-34 2415214-2 1985 In addition, dopamine can prevent neurotensin-induced calcium influx by interacting with dopamine D2-receptors which appear to be completely independent of the adenylate cyclase moiety but are coupled to calcium channels. Dopamine 13-21 neurotensin Rattus norvegicus 34-45 4063843-0 1985 Dopamine-dependent contralateral circling induced by neurotensin applied unilaterally to the ventral tegmental area in rats. Dopamine 0-8 neurotensin Rattus norvegicus 53-64 3938838-1 1985 Microinjection of neurotensin (NT; 2 and 5 micrograms) into the substantia nigra zona compacta caused an increase in dopamine (DA) and DA metabolites in the rodent globus pallidus and striatum which persisted for at least 20 hours after peptide administration. Dopamine 117-125 neurotensin Rattus norvegicus 18-29 6086729-12 1984 Considering the known capacity of neurotensin to activate dopamine neurons in the ventromedial mesencephalon, and the partial mediolateral topographical distribution of dopaminergic projections from this region to the limbic forebrain, it is possible that neurotensin may be activating two distinct populations of dopamine neurons to produce hypothermia and behavioral hyperactivity. Dopamine 58-66 neurotensin Rattus norvegicus 34-45 4005561-1 1985 The dopamine receptor antagonist fluphenazine decanoate, when administered for a total period of 10 months, produced a large increase in neurotensin-like immunoreactivity in dopamine-rich brain areas, such as the nucleus accumbens, the striatum and the frontal cortex. Dopamine 4-12 neurotensin Rattus norvegicus 137-148 4005561-3 1985 The present results provide further evidence in favour of a functional interaction between neurotensin and dopamine in the central nervous system. Dopamine 107-115 neurotensin Rattus norvegicus 91-102 2990164-1 1985 Dopamine reduces the affinity and increases the number of [3H]-neurotensin binding sites in the subcortical limbic forebrain of the rat. Dopamine 0-8 neurotensin Rattus norvegicus 63-74 2982460-8 1985 These data are consistent with the postulate that neurotensin acts in the ventral tegmental area to enhance dopamine release in the diagonal band of Broca, thereby producing hypothermia. Dopamine 108-116 neurotensin Rattus norvegicus 50-61 2989966-7 1985 The results are discussed in terms of a modulatory role of endogenous NT on mesolimbic dopamine neurons. Dopamine 87-95 neurotensin Rattus norvegicus 70-72 2417173-7 1985 For SP, NT and enkephalin the motor response has been blocked by dopamine antagonists. Dopamine 65-73 neurotensin Rattus norvegicus 8-10 2417173-9 1985 These data indicate that SP, SK, enkephalin and NT can activate dopamine neurons in the ventromedial mesencephalon. Dopamine 64-72 neurotensin Rattus norvegicus 48-50 2414815-0 1985 Neurotensin effect on calcium transport and dopamine release in rat striatum. Dopamine 44-52 neurotensin Rattus norvegicus 0-11 6626967-0 1983 Neurotensin facilitates dopamine release in vitro from rat striatal slices. Dopamine 24-32 neurotensin Rattus norvegicus 0-11 6628546-0 1983 Neurotensin potentiates the potassium-induced release of endogenous dopamine from rat striatal slices. Dopamine 68-76 neurotensin Rattus norvegicus 0-11 6628546-3 1983 Neurotensin (2-100 microM) potentiated the potassium-induced release of striatal endogenous DA in a concentration-dependent manner. Dopamine 92-94 neurotensin Rattus norvegicus 0-11 6462447-4 1984 Perfusion of neurotensin in concentrations of 0.05 or 0.1 microgram/microliter in the dorsomedial hypothalamus, lateral hypothalamus, arcuate nucleus or diagonal band of Broca evoked a calcium-dependent efflux of [14C]dopamine. Dopamine 218-226 neurotensin Rattus norvegicus 13-24 6462447-5 1984 The release of dopamine induced by neurotensin was functionally specific since it was: (1) not mimicked by the relatively inactive neurotensin analogue, [D-Arg9]neurotensin; (2) dependent on the morphological locus of the push-pull perfusion; and (3) not accompanied by an efflux of [3H]norepinephrine when the site was double-labelled. Dopamine 15-23 neurotensin Rattus norvegicus 35-46 6462447-7 1984 Moreover, the release of dopamine, but not the temperature change, was abolished when neurotensin was perfused in a calcium-free medium. Dopamine 25-33 neurotensin Rattus norvegicus 86-97 6628546-4 1983 This neurotensin-induced release of DA was completely abolished in calcium-free medium containing EGTA 1 mM. Dopamine 36-38 neurotensin Rattus norvegicus 5-16 6626967-1 1983 Neurotensin, (0.1-10 microM) stimulated the release of [3H]dopamine from rat striatal slices in a calcium-dependent manner, and potentiated the K+-evoked release of [3H]dopamine and endogenous dopamine. Dopamine 59-67 neurotensin Rattus norvegicus 0-11 6628546-7 1983 In additional experiments, we confirmed that the KCl-induced release of DA in the nucleus accumbens was also potentiated b neurotensin. Dopamine 72-74 neurotensin Rattus norvegicus 123-134 6628546-8 1983 These results suggest that neurotensin has a direct effect on the central DA nerve terminals and releases DA in a Ca2+-dependent manner. Dopamine 74-76 neurotensin Rattus norvegicus 27-38 6811728-4 1982 In accord with this view, NT also caused a dose-dependent increase in homovanillic acid and dihydroxyphenylacetic acid, the major metabolites of dopamine, in several brain areas (striatum, olfactory tubercles, nucleus accumbens, frontal cortex and hypothalamus). Dopamine 145-153 neurotensin Rattus norvegicus 26-28 6682440-0 1983 Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. Dopamine 39-47 neurotensin Rattus norvegicus 16-27 6406930-4 1983 Either intracerebroventricular injection of haloperidol (5.0 micrograms/lateral ventricle) or destruction of the mesolimbic dopamine system by 6-hydroxydopamine abolishes the behavioral hyperactivity produced by intraventral tegmental injection of neurotensin (2.5 micrograms/side). Dopamine 124-132 neurotensin Rattus norvegicus 248-259 6406930-5 1983 Using high pressure liquid chromatography with electrochemical detection, we show that neurotensin injection into the ventral tegmental area increases the concentration of dopamine metabolites, 3,4-dihydroxyphenylacetic acid and homovanillic acid in the nucleus accumbens and olfactory tubercles, but not in the striatum. Dopamine 172-180 neurotensin Rattus norvegicus 87-98 6406930-8 1983 Neurotensin-induced behavioral hyperactivity correlates positively with neurotensin-induced changes in the ratio of 3,4-dihydroxyphenylacetic acid to dopamine. Dopamine 150-158 neurotensin Rattus norvegicus 0-11 6406930-8 1983 Neurotensin-induced behavioral hyperactivity correlates positively with neurotensin-induced changes in the ratio of 3,4-dihydroxyphenylacetic acid to dopamine. Dopamine 150-158 neurotensin Rattus norvegicus 72-83 6406930-9 1983 This study indicates that neurotensin acts in the ventral tegmental area to activate the mesolimbic dopamine system. Dopamine 100-108 neurotensin Rattus norvegicus 26-37 6811728-0 1982 Increase in dopamine metabolites in rat brain by neurotensin. Dopamine 12-20 neurotensin Rattus norvegicus 49-60 6866808-1 1983 Neurotensin (NT) injected intracerebroventricularly in rat increases dopamine (DA) turnover in the corpus striatum and nucleus accumbens. Dopamine 69-77 neurotensin Rattus norvegicus 0-11 6866808-1 1983 Neurotensin (NT) injected intracerebroventricularly in rat increases dopamine (DA) turnover in the corpus striatum and nucleus accumbens. Dopamine 69-77 neurotensin Rattus norvegicus 13-15 6866808-1 1983 Neurotensin (NT) injected intracerebroventricularly in rat increases dopamine (DA) turnover in the corpus striatum and nucleus accumbens. Dopamine 79-81 neurotensin Rattus norvegicus 0-11 6866808-1 1983 Neurotensin (NT) injected intracerebroventricularly in rat increases dopamine (DA) turnover in the corpus striatum and nucleus accumbens. Dopamine 79-81 neurotensin Rattus norvegicus 13-15 6866808-8 1983 These experiments demonstrate that NT increases DA turnover in both the nigrostriatal and mesolimbic pathways. Dopamine 48-50 neurotensin Rattus norvegicus 35-37 6811728-3 1982 NT was shown to increase dopa accumulation when compared with saline treatment, suggesting that dopamine synthesis was increased. Dopamine 96-104 neurotensin Rattus norvegicus 0-2 6811728-6 1982 In striatum, an initial increase in dopamine content after 30 micrograms of NT was followed by an increase and a subsequent decrease of dopamine metabolites. Dopamine 36-44 neurotensin Rattus norvegicus 76-78 378326-6 1979 Interactions of neurotensin with other neurotransmitter candidates are also suggested by its presence in areas enriched in norepinephrine, dopamine, serotonin, and substance P. Certain neurotensin localizations suggest an association of the peptide with functional brain systems preferentially involving these regions. Dopamine 139-147 neurotensin Rattus norvegicus 16-27 6261874-7 1981 Dopamine (10(-4)--10(-6) M) stimulated neurotensin release in a dose-dependent manner and this effect was blocked by the dopamine receptor antagonist, haloperidol. Dopamine 0-8 neurotensin Rattus norvegicus 39-50 6261874-9 1981 The results indicate that neurotensin is released by the hypothalamus in vitro; its release is stimulated by membrane depolarization in a Ca2+-dependent manner and may involve an adenylate cyclase mechanism; and dopamine appears to serve as a stimulatory neurotransmitter for neurotensin-containing neurons. Dopamine 212-220 neurotensin Rattus norvegicus 26-37 29462652-12 2018 Our results show that the rewarding effect of NT can be due to the modulation of DA system, since its effects could be blocked by either D1 dopamine or D2 dopamine antagonist preteatment. Dopamine 140-148 neurotensin Rattus norvegicus 46-48 31927144-7 2020 Using high lateral resolution imaging, we observed an increase of neurotensin in the dorsal sub-region of the globus pallidus after dopamine depletion. Dopamine 132-140 neurotensin Rattus norvegicus 66-77 30033601-3 2018 As neurotensin is an important modulator of dopamine and glutamate in these circuits, we investigated its potential role in vulnerability for self-injury, using the pemoline model in rats. Dopamine 44-52 neurotensin Rattus norvegicus 3-14 740049-8 1978 Both neurotensin and [Gln4]-neurotensin also accelerated the disappearance of dopamine, noradrenaline and 5-hydroxytryptamine after inhibition of monoamine synthesis. Dopamine 78-86 neurotensin Rattus norvegicus 5-16 740049-8 1978 Both neurotensin and [Gln4]-neurotensin also accelerated the disappearance of dopamine, noradrenaline and 5-hydroxytryptamine after inhibition of monoamine synthesis. Dopamine 78-86 neurotensin Rattus norvegicus 28-39 29462652-9 2018 Pre-treatment with the D1 dopamine antagonist, blocked the effects of NT. Dopamine 26-34 neurotensin Rattus norvegicus 70-72 29462652-12 2018 Our results show that the rewarding effect of NT can be due to the modulation of DA system, since its effects could be blocked by either D1 dopamine or D2 dopamine antagonist preteatment. Dopamine 155-163 neurotensin Rattus norvegicus 46-48 28522313-0 2017 Neurotensin in the nucleus accumbens reverses dopamine supersensitivity evoked by antipsychotic treatment. Dopamine 46-54 neurotensin Rattus norvegicus 0-11 28522313-3 2017 Chronic antipsychotic treatment elevates neurotensin levels in the nucleus accumbens (NAc), where the neuropeptide modulates dopamine function by signalling through NTS1 receptors. Dopamine 125-133 neurotensin Rattus norvegicus 41-52 28522313-4 2017 We hypothesized that increasing neurotensin activity in the NAc attenuates the expression of antipsychotic-induced dopamine supersensitivity, which is indicated by a potentiated psychomotor response to amphetamine. Dopamine 115-123 neurotensin Rattus norvegicus 32-43 28522313-13 2017 Thus, antipsychotic-induced dopamine supersensitivity enhances the ability of neurotensin in the NAc to regulate dopamine-mediated behaviours, and this likely does not involve changes in local levels of NTS1 receptors or proneurotensin mRNA. Dopamine 28-36 neurotensin Rattus norvegicus 78-89 28522313-13 2017 Thus, antipsychotic-induced dopamine supersensitivity enhances the ability of neurotensin in the NAc to regulate dopamine-mediated behaviours, and this likely does not involve changes in local levels of NTS1 receptors or proneurotensin mRNA. Dopamine 113-121 neurotensin Rattus norvegicus 78-89 28522313-14 2017 We conclude that increasing neurotensin activity could be considered to attenuate antipsychotic-induced dopamine supersensitivity. Dopamine 104-112 neurotensin Rattus norvegicus 28-39